Arcutis Biotherapeutics Yönetim
Yönetim kriter kontrolleri 2/4
Arcutis Biotherapeutics CEO'su Frank Watanabe, Jan2016 tarihinde atandı, in görev süresi 8.83 yıldır. in toplam yıllık tazminatı $ 4.94M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.8% maaş ve 87.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.56% ine doğrudan sahiptir ve bu hisseler $ 6.69M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 4.5 yıldır.
Anahtar bilgiler
Frank Watanabe
İcra Kurulu Başkanı
US$4.9m
Toplam tazminat
| CEO maaş yüzdesi | 12.8% |
| CEO görev süresi | 8.8yrs |
| CEO sahipliği | 0.6% |
| Yönetim ortalama görev süresi | 3yrs |
| Yönetim Kurulu ortalama görev süresi | 4.5yrs |
Son yönetim güncellemeleri
Recent updates
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Nov 15Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$196m |
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$5m | US$634k | -US$262m |
| Sep 30 2023 | n/a | n/a | -US$268m |
| Jun 30 2023 | n/a | n/a | -US$331m |
| Mar 31 2023 | n/a | n/a | -US$327m |
| Dec 31 2022 | US$5m | US$590k | -US$311m |
| Sep 30 2022 | n/a | n/a | -US$311m |
| Jun 30 2022 | n/a | n/a | -US$260m |
| Mar 31 2022 | n/a | n/a | -US$235m |
| Dec 31 2021 | US$4m | US$525k | -US$206m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$150m |
| Mar 31 2021 | n/a | n/a | -US$144m |
| Dec 31 2020 | US$3m | US$442k | -US$136m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$90m |
| Mar 31 2020 | n/a | n/a | -US$63m |
| Dec 31 2019 | US$1m | US$390k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$634k | US$327k | -US$19m |
Tazminat ve Piyasa: Frank 'nin toplam tazminatı ($USD 4.94M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.20M ).
Tazminat ve Kazançlar: Frank şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Frank Watanabe (56 yo)
8.8yrs
Görev süresi
US$4,935,266
Tazminat
Mr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 8.8yrs | US$4.94m | 0.56% $ 6.7m | |
| Co-Founder & Independent Director | no data | US$153.74k | 0.77% $ 9.2m | |
| Senior VP & Chief Medical Officer | 4.3yrs | US$1.67m | 0.15% $ 1.8m | |
| Senior VP & Chief Commercial Officer | 1.2yrs | US$2.03m | Veri yok | |
| Senior VP & Chief Financial Officer | less than a year | Veri yok | 0.041% $ 492.5k | |
| Chief Digital & Technology Officer | 3.1yrs | Veri yok | Veri yok | |
| Vice President of Finance & Investor Relations | no data | Veri yok | Veri yok | |
| VP and Chief Compliance Officer & Privacy Officer | 3.8yrs | Veri yok | Veri yok | |
| Senior VP | 2.8yrs | US$5.14m | 0.042% $ 505.6k | |
| Head of Corporate Communications | 3.3yrs | Veri yok | Veri yok | |
| Head of Marketing & Market Access | 1.2yrs | Veri yok | Veri yok | |
| Vice President of Sales | 1.8yrs | Veri yok | Veri yok |
3.0yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: ARQT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 7.8yrs | US$4.94m | 0.56% $ 6.7m | |
| Co-Founder & Independent Director | 8.6yrs | US$153.74k | 0.77% $ 9.2m | |
| Independent Chairman of the Board | 8.6yrs | US$181.24k | 0.028% $ 329.6k | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Independent Director | 4yrs | US$148.74k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$148.74k | 0.0074% $ 88.4k | |
| Director | 4.3yrs | US$144.24k | 0.14% $ 1.6m | |
| Independent Director | 3.4yrs | US$163.74k | 0.0077% $ 91.5k | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Scientific Advisor | no data | Veri yok | Veri yok |
4.5yrs
Ortalama Görev Süresi
60.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ARQT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).